| | | |
Cmin
|
Cmax
|
|---|
|
Antiretroviral agent
| |
n
|
Mean (SD)
|
Inter-patient CV
|
Intra-patient CV median (IQR)
|
Mean (SD)
|
Inter-patient CV
|
Intra-patient CV median (IQR)
|
|---|
|
Atazanavir
|
400 QD
|
9
|
250.4 (195.4)
|
78.0%
|
57.4 (40.5-86.7)
|
2000.4 (1145.5)
|
57.3%
|
61.9 (44.2-66.0)
|
|
Atazanavir (boosted with ritonavir)
|
300 QD
|
18
|
1065.6 (699.2)
|
65.6%
|
26.3 (15.6-56.1)
|
3525.3 (1459.1)
|
41.4%
|
32.7 (17.2-54.5)
|
|
Lopinavir (boosted with ritonavir)
|
400 BID
|
16
|
6370.0 (2846.4)
|
44.7%
|
23.8 (12.8-75.8)
|
8991.3 (2953.3)
|
32.8%
|
14.0 (12.3-21.7)
|
|
Lopinavir (boosted with ritonavir)
|
800 QD
|
4
|
5356.2 (3882.3)
|
72.5%
|
63.4 (35.2- 115)
|
11151.3 (4433.2)
|
39.8%
|
15.6 ( 7.4-28.4)
|
|
Efavirenz
|
600 QD
|
16
|
2196.9 (1209.2)
|
55.0%
|
17.7 (10.5-25.1)
|
3929.4 (2060.6)
|
52.4%
|
15.5 (12.8-27.9)
|
|
Nevirapine
|
200 BID
|
11
|
5693.6 (2586.8)
|
45.4%
|
13.9 (10.2-27.8)
|
6490.9 (2454.9)
|
37.8%
|
10.7 ( 7.8-19.6)
|
|
Nevirapine
|
400 QD
|
8
|
5027.9 (2867.2)
|
57.0%
|
21.3 (12.1-44.9)
|
6924.4 (2761.1)
|
39.9%
|
22.8 ( 8.3-53.8)
|
-
SD, Standard deviation; CV, Coefficient of Variation; IQR, Interquartile Range.
